Yasunaga Yoshikawa

Dr. Yasunaga Yoshikawa

Faculty of Veterinary Medicine, Kitasato University, Ōwada, Aomori, Japan
orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 July 2015 in BMC Veterinary Research
Verified
Journal Article
Open access
PDF file
Yasunaga YoshikawaYasunaga Yoshikawa
Yasunaga Yoshikawa
MMMasami Morimatsu
Masami Morimatsu
KOKazuhiko Ochiai
Kazuhiko Ochiai
TIToshina Ishiguro-Oonuma
Toshina Ishiguro-Oonuma
SWSeiichi Wada
Seiichi Wada
KWKiyotaka Watanabe
Kiyotaka Watanabe
Mammary tumors are the most common tumor type in intact female dogs. Recently, the breast cancer 2 early onset (BRCA2) gene was proposed to be associated with tumorigenesis in dogs. The expression level of BRCA2 is important for its DNA repair function in mammalian cells, and its expression level is linked to tumorigenesis in mammary tissue. However, the expression of canine BRCA2 in mammary tumors is unclear. BRCA2 mRNA levels were compared between seven mammary gland samples and seventeen mammary tumor samples isolated from dogs. The expression level of canine BRCA2 in mammary tumor samples was lower than levels in mammary gland samples. We attempted to identify why the BRCA2 expression level was decreased in mammary tumor samples by promoter sequencing analysis; however, we did not find any mutations in the canine BRCA2 promoter that altered BRCA2 transcription levels. We did detect two types of BRCA2 splice variants in 8 mammary tumor samples. One of the variants induced a frame-shift mutation that could lead to nonsense-mediated mRNA decay, a ubiquitous cellular mechanism that eliminates mRNA containing a premature termination codon. Reduced expression of canine BRCA2 mRNA in mammary tumor samples is a possible mechanism to explain mammary tumor development in dogs. One possible reason for reduced BRCA2 mRNA levels in these tumor samples was nonsense-mediated mRNA decay, not mutations in the BRCA2 promoter region. While it remains unclear why canine BRCA2 expression levels are reduced in mammary tumor samples, this study found that the expression level of BRCA2 was associated with canine mammary tumorigenesis.

18 October 2018 in PLOS Genetics
Verified
Journal Article
Open access
PDF file
AMAnna Motnenko
Anna Motnenko
CLChih-Chao Liang
Chih-Chao Liang
DYDi Yang
Di Yang
DLDavid Lopez-Martinez
David Lopez-Martinez
Yasunaga YoshikawaYasunaga Yoshikawa
Yasunaga Yoshikawa
MCMartin Cohn
Martin Cohn
The Fanconi Anemia (FA) pathway is important for repairing interstrand crosslinks (ICLs) between the Watson-Crick strands of the DNA double helix. An initial and essential stage in the repair process is the detection of the ICL. Here, we report the identification of UHRF2, a paralogue of UHRF1, as an ICL sensor protein. UHRF2 is recruited to ICLs in the genome within seconds of their appearance. We show that UHRF2 cooperates with UHRF1, to ensure recruitment of FANCD2 to ICLs. A direct protein-protein interaction is formed between UHRF1 and UHRF2, and between either UHRF1 and UHRF2, and FANCD2. Importantly, we demonstrate that the essential monoubiquitination of FANCD2 is stimulated by UHRF1/UHRF2. The stimulation is mediating by a retention of FANCD2 on chromatin, allowing for its monoubiquitination by the FA core complex. Taken together, we uncover a mechanism of ICL sensing by UHRF2, leading to FANCD2 recruitment and retention at ICLs, in turn facilitating activation of FANCD2 by monoubiquitination. Fanconi Anemia is a genetic disease where patients typically have congenital abnormalities, develop bone marrow failure and suffer from cancer predisposition. The cells in patients have a reduced ability to repair a type of DNA damage where the two strands of the DNA double helix are physically linked together, and this failure in repair is believed to contribute to cause of the disease. Many proteins are involved in repairing this type of DNA damage in healthy individuals, via a complex DNA repair pathway called the Fanconi Anemia pathway. Here, we report the identification of a new player in this pathway. The protein, called UHRF2, is able to sense the DNA damage in the genome, and thereby help to initiate the healthy repair of the damage. In addition to improving our molecular understanding of the Fanconi Anemia pathway, in the long term, this new knowledge could have medical implications for diagnosis and therapy relating to pathologies involving this type of DNA damage.

12 October 2012 in PLOS ONE
Verified
Journal Article
Open access
PDF file
Yasunaga YoshikawaYasunaga Yoshikawa
Yasunaga Yoshikawa
KOKazuhiko Ochiai
Kazuhiko Ochiai
MMMasami Morimatsu
Masami Morimatsu
YSYu Suzuki
Yu Suzuki
SWSeiichi Wada
Seiichi Wada
KWKiyotaka Watanabe
Kiyotaka Watanabe
Mammary tumors are the most common tumor type in both human and canine females. Mutations in the breast cancer susceptibility gene, BRCA2, have been found in most cases of inherited human breast cancer. Similarly, the canine BRCA2 gene locus has been associated with mammary tumors in female dogs. However, deleterious mutations in canine BRCA2 have not been reported, thus far. The BRCA2 protein is involved in homologous recombination repair via its interaction with RAD51 recombinase, an interaction mediated by 8 BRC repeats. These repeats are 26-amino acid, conserved motifs in mammalian BRCA2. Previous structural analyses of cancer-associated mutations affecting the BRC repeats have shown that the weakening of RAD51's affinity for even 1 repeat is sufficient to increase breast cancer susceptibility. In this study, we focused on 2 previously reported canine BRCA2 mutations (T1425P and K1435R) in BRC repeat 3 (BRC3), derived from mammary tumor samples. These mutations affected the interaction of canine BRC3 with RAD51, and were considered deleterious. Two BRC3 mutations (K1440R and K1440E), reported in human breast cancer patients, occur at amino acids corresponding to those of the K1435R mutation in dogs. These mutations affected the interaction of canine BRC3 with RAD51, and may also be considered deleterious. The two BRC3 mutations and a substitution (T1430P), corresponding to T1425P in canine BRCA2, were examined for their effects on human BRC3 function and the results were compared between species. The corresponding mutations and the substitution showed similar results in both human and canine BRC3. Therefore, canine BRCA2 may be a good model for studying human breast cancer caused by BRCA2 mutations.

26 September 2013 in Molecular Biology Reports
Verified
Journal Article
Closed access
PDF file
YSYoshinori Shimamoto
Yoshinori Shimamoto
HKHiroshi Kitamura
Hiroshi Kitamura
KNKimie Niimi
Kimie Niimi
Yasunaga YoshikawaYasunaga Yoshikawa
Yasunaga Yoshikawa
FHFumio Hoshi
Fumio Hoshi
ETEiki Takahashi
Eiki Takahashi

3 April 2012 in BMC Research Notes
Verified
Journal Article
Open access
PDF file
Yasunaga YoshikawaYasunaga Yoshikawa
Yasunaga Yoshikawa
MMMasami Morimatsu
Masami Morimatsu
KOKazuhiko Ochiai
Kazuhiko Ochiai
KOKento Okuda
Kento Okuda
TTTakahiro Taoda
Takahiro Taoda
KWKiyotaka Watanabe
Kiyotaka Watanabe
Mammary tumors are the most common tumor type in both human and canine females. In women, carriers of mutations in BRCA2, a tumor suppressor gene product, have a higher risk of breast cancer. Canine BRCA2 has also been suggested to have a relationship with mammary tumors. However, clearly deleterious BRCA2 mutations have not been identified in any canine mammary tumors, as appropriate methods to detect mutations or a consensus BRCA2 sequence have not been reported.

8 July 2022 in Parasites & Vectors
Verified
Journal Article
Open access
PDF file
Yasunaga YoshikawaYasunaga Yoshikawa
Yasunaga Yoshikawa
SKShunta Kimura
Shunta Kimura
ASAkira Soga
Akira Soga
MSMakoto Sugiyama
Makoto Sugiyama
AUAki Ueno
Aki Ueno
HIHiromi Ikadai
Hiromi Ikadai
Background: Malaria is a major global parasitic disease caused by species of the genus Plasmodium. Zygotes of Plasmodium spp. undergo meiosis and develop into tetraploid ookinetes, which differentiate into oocysts that undergo sporogony. Homologous recombination (HR) occurs during meiosis and introduces genetic variation. However, the mechanisms of HR in Plasmodium are unclear. In humans, the recombinases DNA repair protein Rad51 homolog 1 (Rad51) and DNA meiotic recombinase 1 (Dmc1) are required for HR and are regulated by breast cancer susceptibility protein 2 (BRCA2). Most eukaryotes harbor BRCA2 homologs. Nevertheless, these have not been reported for Plasmodium. Methods: A Brca2 candidate was salvaged from a database to identify Brca2 homologs in Plasmodium. To confirm that the candidate protein was Brca2, interaction activity between Plasmodium berghei (Pb) Brca2 (PbBrca2) and Rad51 (PbRad51) was investigated using a mammalian two-hybrid assay. To elucidate the functions of PbBrca2, PbBrca2 was knocked out and parasite proliferation and differentiation were assessed in mice and mosquitoes. Transmission electron microscopy was used to identify sporogony. Results: The candidate protein was conserved among Plasmodium species, and it was indicated that it harbors critical BRCA2 domains including BRC repeats, tower, and oligonucleotide/oligosaccharide-binding-fold domains. The P. berghei BRC repeats interacted with PbRad51. Hence, the candidate was considered a Brca2 homolog. PbBrca2 knockout parasites were associated with reduced parasitemia with increased ring stage and decreased trophozoite stage counts, gametocytemia, female gametocyte ratio, oocyst number, and ookinete development in both mice and mosquitoes. Nevertheless, the morphology of the blood stages in mice and the ookinete stage was comparable to those of the wild type parasites. Transmission electron microscopy results showed that sporogony never progressed in Brca2-knockout parasites. Conclusions: Brca2 is implicated in nearly all Plasmodium life cycle stages, and especially in sporogony. PbBrca2 contributes to HR during meiosis. Graphical